News

The Pharma Letter31m
Novo Nordisk keeps nose ahead of Lilly with oral GLP-1 filing
Shares in Eli Lilly shot up last Thursday after the US pharma major announced positive top-line Phase III results from ...
Fierce Pharma1d
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
FDA stops sale of generic versions of Ozempic and Wegovy: What to do if you’re taking them
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
Why Novo Nordisk Stock Popped Today
Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP ...
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Is Novo Nordisk A/S (NVO) The Top Falling Stock with Unusual Volume?
We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at ...
Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly
Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...
24/7 Wall St.2d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Medical Dialogues1d
As Ozempic, Wegovy Take Priority, Novo Nordisk Winds Down Insulin Portfolio In India
Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...
Futurism on MSN4d
Novo Nordisk Is Getting Absolutely Destroyed
Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...